Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
As a rare, progressive disease with an evolving treatment landscape, there is a need for better understanding of treatment patterns and experience for patients with immunoglobulin A nephropathy (IgAN). To address this need, the PERFORM™ Patient Registry (PPR) has been created to assess the longitudinal disease characteristics, healthcare utilization, clinical management, and treatment utilization patterns of patients treated with delayed-release budesonide (Tarpeyo®) for IgAN in the United States (US). The aim of this presentation is to describe the creation of the PPR and present initial demographics of participants enrolled.
PPR is an observational patient registry designed to collect longitudinal data on patients receiving Tarpeyo®. Consented US patients treated with Tarpeyo® for IgAN are recruited from across the US through specialty pharmacy and from a prior registry. Using the PicnicHealth Research Platform, retrospective and prospective medical records for consented participants are retrieved in any format, across all providers and sites of care, digitized and compiled into a unified patient record that is provided back to the participant. Key data related to IgAN are then extracted from participants’ medical records through artificial intelligence-enhanced chart review to curate a de-identified dataset for research. Enrollment in PPR began in March 2025 and is ongoing, with plans to enroll approximately 600 participants including pediatric, adolescent, adult, and post-transplant participants. The demographics of the currently enrolled participants were described for this initial analysis of PPR.
As of July 2025, 83 participants had enrolled in PPR. Participants had a mean (standard deviation) age of 43 (14) years at enrollment. Among participants, 61% were male, 11% were Hispanic/Latino, 72% were White, 4% were Black/African American, 12% were Asian, and 10% were of other races.
While enrollment is ongoing, the current PPR population comprises a varied cohort of patients treated with Tarpeyo® for IgAN. This registry will allow for further understanding of IgAN management and outcomes for patients treated with Tarpeyo® for IgAN.
This abstract was also submitted for the American Society of Nephrology Kidney Week 2025 congress.
